Insider Selling: BioSyent Inc. (CVE:RX) Director Sells C$25,404.00 in Stock

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00.

BioSyent Stock Performance

Shares of RX stock opened at C$11.00 on Thursday. BioSyent Inc. has a 12-month low of C$7.66 and a 12-month high of C$11.45. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The firm’s 50 day moving average is C$10.39 and its 200 day moving average is C$9.53. The stock has a market capitalization of C$127.49 million, a P/E ratio of 18.33 and a beta of 0.93.

BioSyent (CVE:RX) last released its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, hitting the consensus estimate of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The business had revenue of C$8.95 million for the quarter, compared to the consensus estimate of C$8.80 million. Research analysts expect that BioSyent Inc. will post 0.6785935 earnings per share for the current year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.